Abstract
VEGFR and mTOR inhibitors are broadly used in metastatic renal cell carcinoma (mRCC) therapy, and sequential first-line pazopanib (VEGFR inhibitor) and second-line everolimus (mTOR inhibitor) is a standard treatment option. Nivolumab and lenvatinib/everolimus combination was recently approved in Europe for use in mRCC after previous therapy. Prospective routine data on sequential therapy including nivolumab and/or lenvatinib are missing. This is a prospective, noninterventional study, which evaluates the effectiveness, tolerability, safety and quality of life following 450 patients with mRCC starting either on pazopanib as first-line therapy or third-line everolimus plus/minus lenvatinib following nivolumab. Adults with histologically confirmed mRCC of any subtype, who have a life expectancy of at least 6 months, are eligible.
Keywords:
Afinitor; Opdivo; PAZOREAL; Votrient; everolimus; mRCC; metastatic renal cell carcinoma; nivolumab; noninterventional; pazopanib.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / genetics
-
Carcinoma, Renal Cell / pathology
-
Disease-Free Survival
-
Drug-Related Side Effects and Adverse Reactions / pathology
-
Everolimus / administration & dosage*
-
Everolimus / adverse effects
-
Female
-
Humans
-
Indazoles
-
Male
-
Middle Aged
-
Molecular Targeted Therapy
-
Neoplasm Metastasis
-
Nivolumab
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Pyrimidines / administration & dosage*
-
Pyrimidines / adverse effects
-
Quality of Life
-
Sulfonamides / administration & dosage*
-
Sulfonamides / adverse effects
-
TOR Serine-Threonine Kinases / antagonists & inhibitors
-
TOR Serine-Threonine Kinases / genetics
-
Vascular Endothelial Growth Factor Receptor-1 / antagonists & inhibitors
-
Vascular Endothelial Growth Factor Receptor-1 / genetics
Substances
-
Antibodies, Monoclonal
-
Indazoles
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Sulfonamides
-
Nivolumab
-
pazopanib
-
Everolimus
-
MTOR protein, human
-
Vascular Endothelial Growth Factor Receptor-1
-
TOR Serine-Threonine Kinases